Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Aren Petrosyan
100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
Since August 26, 2023, Women’s Equality Day in the United States has marked the beginning of a special OncoDaily tradition – the 100 Influential Women in Oncology. On this day, we launched an initiative to recognize 100 inspiring women making a difference in oncology around the world, highlighting 10 remarkable women each week.
How to Become a Nobel Laureate: BIGR Analysis of 125 Years of Scientific Breakthroughs
Every October, the global scientific community pauses for a handful of phone calls from Stockholm. A sleepy professor in Boston or Kyoto answers a call from an unknown Swedish number, and in an instant, their life’s work is elevated to immortal status. When looking at the complete record of Nobel Laureates in Physiology or Medicine, it becomes clear that while raw genius is required, where that genius spends its time matters almost as much. Nobel-winning discoveries rarely happen in isolation.
OCRF and News Corp Australia Launch “Over It” Campaign to Close the Ovarian Cancer Survival Gap
Ovarian Cancer Research Foundation (OCRF) and News Corp Australia have launched Over It, a national campaign calling on the Australian Government to increase investment in ovarian cancer research and address the disease’s persistent survival gap. Launched on October 11, 2026, the campaign seeks A$21 million annually for each of the next four years, totalling A$84 million, followed by sustained research investment until ovarian cancer survival exceeds 90%.
100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
Since August 26, 2023, Women’s Equality Day in the United States has marked the beginning of a special OncoDaily tradition – the 100 Influential Women in Oncology. On this day, we launched an initiative to recognize 100 inspiring women making a difference in oncology around the world, highlighting 10 remarkable women each week.
Who Shaped Oncology in the First Half of 2026: Breaking Down Approvals by Indications
Key takeaways 22 FDA approvals 15 distinct indications 5 breast cancer approvals 8 blood cancers approvals This article focuses on where the 2026 approvals landed by their indications. The 22 approvals covered 15 distinct indications, with breast cancer leading the list with 5 approvals. Blood cancers received 8 approvals across 7 indications overall. Multiple myeloma, ovarian cancer, and bladder cancer got 2 approvals each.
Zipporah Ali Named Candidate for UICC Board of Directors 2026–2028
Zipporah Ali, a palliative care physician and public health specialist based in Nairobi, Kenya, has been named a candidate for the Union for International Cancer Control (UICC) Board of Directors for the 2026–2028 term. Dr Ali has more than three decades of experience in cancer care, palliative care, advocacy, public health, and health policy.
100 Influential Women in Oncology in 2026: Key Opinion Leaders in Social Media and Beyond
Since August 26, 2023, Women’s Equality Day in the United States has marked the beginning of a special OncoDaily tradition – the 100 Influential Women in Oncology. On this day, we launched an initiative to recognize 100 inspiring women making a difference in oncology around the world, highlighting 10 remarkable women each week.
Which Drugs and Pharma Shaped Oncology in the First Half of 2026? Breaking Down FDA Approvals
Key takeaways 22 FDA approvals 19 distinct drugs 16 pharma companies 5 first-time approvals This article focuses on each oncology approval in the first half of 2026 and where they came from: which company built the drug, which one owns it now, and how a therapy approved a decade ago can still be making headlines today. AstraZeneca had the most approvals in the first half of 2026: three credited to it directly, plus two ADCs it co-developed with Daiichi Sankyo.
AstraZeneca and Daiichi Sankyo Partner with Summit Therapeutics to Study Datopotamab Deruxtecan and Ivonescimab
A new clinical collaboration will explore whether combining a TROP2-directed antibody-drug conjugate with a bispecific immunotherapy can expand treatment possibilities across solid tumors. AstraZeneca and Daiichi Sankyo have entered into a clinical trial collaboration with Summit Therapeutics to evaluate datopotamab deruxtecan in combination with ivonescimab.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Aren
Contact Aren, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack